Virus safety of human blood, plasma, and derived products

Güertler, Lutz

doi:10.1016/s0049-3848(02)00151-2

Cited by 26 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemical or biochemical inactivation procedures include solvent/detergent treatment, modulation of pH values, enzymatic conditioning, and ethanol fi xation [14,15] . It is, however, important to investigate several different inactivation and clearance techniques, so that a minimum of product damage and a maximum of reduction of infectivity are obtained.…”

Section: Discussionmentioning

confidence: 99%

Inactivation of Hantaan Virus-Containing Samples for Subsequent Investigations outside Biosafety Level 3 Facilities

et al. 2005

View full text Add to dashboard Cite

Objectives: The potential risk of accidental infection by hantaviruses in a clinical or research laboratory necessitates special precautionary measures. A biosafety program must address handling and disposal of infectious materials as well as appropriate virus inactivation or depletion procedures to permit necessary further processing of specimens outside the biosafety level 3 laboratory. Methods: To study the elimination of hantavirus infectivity, the effects of different chemical and physical inactivation and depletion procedures were investigated on Hantaan virus-containing materials. An infectivity assay for hantaviruses was utilised to verify these procedures which are commonly preceding investigations such as ELISA, flow cytometry analysis, Western blot or immunofluorescence assay. Results: Chemical inactivation with methanol, paraformaldehyde, acetone/methanol and detergent-containing lysis buffer as well as physical forces such as UV irradiation and filtration efficiently reduced viral infectivity in infected cells and their supernatants below the detection limit. Conclusion: The virus inactivation and depletion methods described herein are suitable to prepare non-infectious samples for further use in immunological, virological and cell-biological assays.

show abstract

Section: Discussionmentioning

confidence: 99%

Inactivation of Hantaan Virus-Containing Samples for Subsequent Investigations outside Biosafety Level 3 Facilities

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The virus is transmitted effectively after close contact exposures and the reported seroprevalence ranges from 15 to 60% in children 6-19 years old, from 30 to 60% in adults and is more than 85% in the geriatric population [Tsujimura et al, 1995]. In addition to the natural respiratory route of transmission, B19 virus may also be transmitted by blood and blood derivatives, due to the consistent viremia which characterises the acute infection, even if asymptomatic [Guertler, 2002].…”

Section: Introductionmentioning

confidence: 99%

Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis

Azzi

Manaresi

Zakrzewska

et al. 2004

Journal of Medical Virology

View full text Add to dashboard Cite

Parvovirus B19 infection occurs very frequently in patients with haemophilia on account of its transmission with plasma derivatives. In order to achieve a more defined serological pattern for the study of the role of B19 infection in haemophilic arthritis, 53 serum samples from 37 patients with haemophilic arthritis were investigated for the presence of IgG immune response against B19 VP2 and VP1 linear epitopes and VP2 conformational antigen compared to the serological reactivity against B19 NS1 and to the presence of B19 DNA in the synovial membranes. An IgG immune response against VP1 and VP2 linear epitopes was detected by immunoblot assay using recombinant proteins expressed in Escherichia coli. Specific IgG against VP2 and VP1 linear epitopes were present in 84.90 and 92.45% of haemophilic arthritis patients and in 28.0 and 64.0% of the controls (P<0.001) respectively. All 53 sera of the haemophiliacs (100%) and 66.0% of the controls (P<0.001) were IgG positive and IgM negative against VP2 structural epitopes. Specific IgG against VP2 linear epitopes, which are a serological marker of active or very recent B19 infection, proved to be significantly associated with the presence of anti-NS1 antibodies and with the presence of B19 DNA in synovial tissue in patients with haemophilic arthritis. In conclusion, in these patients the presence of B19 IgG anti-VP2 linear epitopes, in absence of IgM anti-VP2 structural antigens, can be a useful serological marker to diagnose active, recent or persistent B19 infection.

show abstract

“…In Canada, the infectious disease risks of transfusion are minimized through multiple steps, including blood collection from volunteer unpaid donors, donor interview and selection procedures, careful aseptic technique procedures for collection and infusion, diversion of the first 40 mL of blood collected into a diversion pouch, donor screening by serological and other tests ( (11), and viral inactivation procedures included in the manufacturing of plasma-derived products (Table 2) (12)(13)(14)(15).…”

mentioning

confidence: 99%

Transfusion and Risk of Infection in Canada: Update 2005

MacDonald¹,

Scott²,

Giulivi³

2005

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

In Canada and other countries, many steps are taken to minimize the risk of infection through the transfusion of blood or blood products (1). However, the infection risk can never be zero because these are biological products that are taken from living donors who are never 'germ free' (2). This is in contrast to drugs that can be manufactured de novo under sterile conditions in a laboratory. The present note provides an update on transfusion infection risks in Canada. It replaces the 2004 note (3) and may be helpful to practitioners in discussions with patients and parents toward obtaining informed consent before blood or blood product administration.

show abstract

Virus safety of human blood, plasma, and derived products

Cited by 26 publications

References 22 publications

Inactivation of Hantaan Virus-Containing Samples for Subsequent Investigations outside Biosafety Level 3 Facilities

Inactivation of Hantaan Virus-Containing Samples for Subsequent Investigations outside Biosafety Level 3 Facilities

Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis

Transfusion and Risk of Infection in Canada: Update 2005

Contact Info

Product

Resources

About